CA
PCVX icon

Continuum Advisory’s Vaxcyte PCVX Stock Holding History

Continuum Advisory’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.51K Buy
+26
New +$1.41K ﹤0.01% 1789
2025
Q2 		– Sell
-63
Closed -$2.38K – 1229
2025
Q1 		$2.38K Buy
63
+17
+37% +$1.36K ﹤0.01% 1295
2024
Q4 		$3.77K Sell
46
-46
-50% -$4.57K ﹤0.01% 1207
2024
Q3 		$8.53K Sell
92
-2
-2% -$180 ﹤0.01% 1040
2024
Q2 		$7.1K Sell
94
-6
-6% -$408 ﹤0.01% 1024
2024
Q1 		$6.56K Buy
+100
New +$6.92K ﹤0.01% 1026

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Continuum Advisory's PCVX Position: Q2 2026 in Review

Continuum Advisory opened a new position in Vaxcyte (PCVX) in Q2 2026: 26 shares worth $1.51K. The stake represents ﹤0.01% of the portfolio and ranks #1789 among its holdings. This is a return to the name: Continuum Advisory previously reported a position in PCVX as recently as Q1 2025.

Continuum Advisory first reported a position in PCVX in Q1 2024 and has held it in 6 quarters since. The position peaked at $8.53K in Q3 2024. 331 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

  • Continuum Advisory held 26 shares of Vaxcyte worth $1.51K as of Q2 2026.
  • Vaxcyte was a new Continuum Advisory position in Q2 2026.
  • Vaxcyte made up ﹤0.01% of Continuum Advisory's portfolio in Q2 2026, its #1789 holding.
  • Continuum Advisory first reported a position in Vaxcyte in Q1 2024 and has held it in 6 quarters since.
  • Continuum Advisory's Vaxcyte position peaked at $8.53K in Q3 2024.
  • 331 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on Continuum Advisory's 13F filing for Q2 2026, filed 6 Aug 2026.